BR112016026443A8 - compostos heterocíclicos deuterados, seus usos, e composição farmacêutica - Google Patents
compostos heterocíclicos deuterados, seus usos, e composição farmacêuticaInfo
- Publication number
- BR112016026443A8 BR112016026443A8 BR112016026443A BR112016026443A BR112016026443A8 BR 112016026443 A8 BR112016026443 A8 BR 112016026443A8 BR 112016026443 A BR112016026443 A BR 112016026443A BR 112016026443 A BR112016026443 A BR 112016026443A BR 112016026443 A8 BR112016026443 A8 BR 112016026443A8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- compounds
- deuterated
- heterocyclic compounds
- salts
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
compostos heterocíclicos deuterados, seus usos, e composição farmacêutica. a presente invenção se refere a compostos deuterados e opcionalmente detectavelmente marcados de fórmula (i): r1 ? a ? r2 e de fórmula (v), e seus sais, sendo que r1, r2, a e x10-x19 possuem quaisquer valores definidos nesse pedido. também estão incluídas composições farmacêuticas que compreendem tais compostos e sais, e métodos para usar tais compostos e sais como agentes de imagem, em particular, na medida do sinal radioativo do composto associado com os depósitos de amiloide e/ou agregados de proteína tau.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992717P | 2014-05-13 | 2014-05-13 | |
| US61/992,717 | 2014-05-13 | ||
| PCT/EP2015/060447 WO2015173225A1 (en) | 2014-05-13 | 2015-05-12 | Deuterated heterocyclic compounds and their use as imaging agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112016026443A2 BR112016026443A2 (pt) | 2017-08-15 |
| BR112016026443A8 true BR112016026443A8 (pt) | 2021-07-06 |
| BR112016026443B1 BR112016026443B1 (pt) | 2023-07-04 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014615A (es) | Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes. | |
| BR112017016311A2 (pt) | derivados de 9h-pirrolo-dipiridina | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| CY1122177T1 (el) | Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη | |
| BR112018009281A2 (pt) | composições para tratar atrofia muscular espinhal | |
| BR112017009701A2 (pt) | composto e métodos para a preparação de um composto | |
| BR112018075284A2 (pt) | derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os | |
| BR112017010893A2 (pt) | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| BR112015023142A8 (pt) | moduladores do p2x7,seu uso, processo de preparação e composição farmacêutico que os compreende | |
| BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| BR112017009194A2 (pt) | tetra-hidropiranos substituídos e método de uso | |
| CL2018002335A1 (es) | Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1 | |
| BR112016002012A2 (pt) | compostos de sulfonamida heterocíclica substituída úteis como moduladores de trpa1 | |
| BR112016008644A2 (pt) | Inibidor de dinamina 2 para uso no tratamento de uma miopatia centronuclear; método para identificar ou triar moléculas úteis no tratamento de uma miopatia centronuclear, de preferência, xlcnm; e composição farmacêutica | |
| BR112016016853A2 (pt) | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso | |
| UY35305A (es) | Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap) | |
| BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
| BR112015012949A2 (pt) | composto, composição farmaceutica, uso de um composto, dispositivo inalatório e kit | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| BR112016022749A2 (pt) | compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2 | |
| BR112016028022A2 (pt) | compostos de sulfonamida e seus usos como inibidores de stat5 | |
| BR112017020796A2 (pt) | compostos, composição farmacêutica e kit | |
| BR112018003489A2 (pt) | n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2015, OBSERVADAS AS CONDICOES LEGAIS |